晚期非小细胞肺癌免疫治疗的预后影响因素分析  

Analysis on prognostic influencing factors of immunotherapy for advanced non-small cell lung cancer

作　　者：邓凯 李承慧[1,2] DENG Kai;LI Chenghui(Anqing Medical Center,Anhui Medical University,Anqing,Anhui 246000,China;Fifth Affiliated Clinical Medical College,Anhui Medical University,Anqing,Anhui 246000,China)

机构地区：[1]安徽医科大学安庆医学中心,安徽安庆246000 [2]安徽医科大学附属第五临床医学院,安徽安庆246000

出　　处：《重庆医学》2025年第2期430-435,共6页Chongqing Medical Journal

基　　金：吴阶平医学基金会临床科研专项(320.6750.2022-19-45)。

摘　　要：目的 探讨晚期非小细胞肺癌(NSCLC)患者免疫治疗的预后相关影响因素,为临床治疗及评估患者预后提供参考。方法 回顾性分析2019年10月至2022年6月安徽医科大学安庆医学中心收治的132例接受免疫治疗的晚期NSCLC患者的临床资料,统计总生存(OS)时间和无进展生存(PFS)时间,采用Cox单因素和多因素模型分析其预后相关影响因素。结果 132例患者中位OS时间为20.10个月,中位PFS时间为14.95个月。多因素分析结果显示,美国东部肿瘤协作组(ECOG)评分、治疗线数、接受姑息性放疗是接受免疫治疗的晚期NSCLC患者OS时间的独立影响因素(P<0.05),血红蛋白、C反应蛋白(CRP)、ECOG评分、治疗线数是接受免疫治疗的晚期NSCLC患者PFS时间的独立影响因素(P<0.05)。结论 血红蛋白≥110 g/L、CRP<6 mg/L、ECOG评分0~1分、一线免疫治疗、接受姑息性放疗的患者更能从免疫治疗中获益。Objective To explore the prognosis related influencing factors of immunotherapy in the patients with advanced non-small cell lung cancer(NSCLC)to provide reference for clinical treatment and prognosis evaluation of the patients.Methods The clinical data of 132 patients with advanced NSCLC receiving the immunotherapy admitted and treated in the Anqing Medical Center of Anhui Medical University from October 2019 to June 2022 were retrospectively analyzed.The overall survival(OS)and progression-free survival(PFS)of the patients were statistically analyzed.The Cox univariate and multivariate models were used to analyze the prognosis related influencing factors.Results The median OS time in 132 cases was 20.10 months and the median PFS time was 14.95 months.The results of multi-factor analysis showed that the ECOG score,number of treatment lines and receiving palliative radiotherapy were the independent influencing factors of OS time in the patients with advanced NSCLC(P<0.05).Hemoglobin,C-reactive protein(CRP),ECOG score and number of treatment lines were the independent risk factors of PFS time in the patients with advanced NSCLC(P<0.05).Conclusion The patients with hemoglobin≥110 g/L,CRP<6 mg/L,ECOG score 0-1 point,first line immunotherapy,receiving palliative radiotherapy could obtain the benefit from immunotherapy.

关 键 词：晚期肺癌 非小细胞肺癌 免疫治疗 姑息性放疗 预后 

分 类 号：R734.2[医药卫生—肿瘤]